ClinicalTrials.gg
RecruitingNCT07372625Updated Aug 12, 2026

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

A Phase 1 interventional study of metformin hydrochloride 500 mg tablet and rosuvastatin 10 mg tablet in TP53 Y220C Mutation and Advanced Solid Tumors, sponsored by PMV Pharmaceuticals, Inc. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by PMV Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Read the detailed description

Rezatapopt (PC14586) is a first-in-class oral, small molecule p53 reactivator that is selective for the TP53 Y220C mutation.

This Phase 1, open-label, drug-drug interaction study will investigate the effect of multiple oral doses of rezatapopt on the pharmacokinetics (PK) of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation. This study will consist of 2 parts, Part A and Part B.

Part A is a 24-day drug-drug interaction (DDI) portion that follows a fixed- sequence design, including a screening period and 2 treatment periods.

In Treatment Period 1 patients will receive metformin and rosuvastatin, followed by repaglinide and midazolam. Patients will not receive rezatapopt during Treatment Period 1.

Following washout, in Treatment Period 2 which will begin on Day 6, patients will receive 2000 mg rezatapopt administered orally once daily along with metformin and rosuvastatin, and then repaglinide and midazolam in accordance with the fixed-sequence dosing schedule. Serial PK samples will be collected on designated days throughout Part A.

Patients who complete Part A without suspected disease progression and unacceptable toxicity or another discontinuation criterion and who are deemed likely to continue benefiting from the study treatment, will be allowed to continue treatment with rezatapopt in Part B.

In Part B, patients will receive 2000 mg rezatapopt orally daily in 21-day cycles, up to Cycle 33 (approximately 2 years of rezatapopt treatment, inclusive of Part A) or until another discontinuation criterion is met.

A maximum of approximately 14 patients are planned to enroll in this study.

02

Conditions studied

  • TP53 Y220C Mutation
  • Advanced Solid Tumors

Keywords

  • Y220C
  • PC14586
  • PMV Pharma
  • PMV
  • rezatapopt
  • Phase 1
  • metformin
  • rosuvastatin
  • repaglinide
  • midazolam
  • DDI
03

In context

Lead sponsor

PMV Pharmaceuticals, Inc is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written
  2. 18 years and older
  3. performance status (PS) score of 0 or 1
  4. Confirmed locally advanced or solid with a TP53 Y220C mutation identified through a tumor-tissue based (e.g., FoundationOneCDx, PathGroup, Caris WES, MSK IMPACT, TEMPUS) or a liquid- based (e.g., Caris, MSK Access) NGS molecular test.

    - Patients with primary CNS tumors are allowed to enroll

  5. Patients with castration-resistant prostate cancer must have ongoing androgen deprivation therapy with a gonadotropin-releasing hormone analog or inhibitor or orchiectomy (medical or surgical castration)
  6. Adequate organ function
  7. ≥3 months as assessed by the Investigator

Exclusion criteria

Exclusion Criteria:

  1. Patients with ovarian, breast, lung, or endometrial tumors who are eligible for the PYNNACLE Phase 2 trial (NCT04585750), unless the corresponding cohort in the PYNNACLE trial is closed to enrollment at the time of screening (to avoid overlap with that study).
  2. Treatment, food, or drink with any of the following:

    • Any systemic anticancer therapies, including but not limited to chemotherapy, small molecule, biologic, or hormonal agents from a previous treatment regimen, or anticancer agents from clinical study within 21 days or 5 half-lives (whichever is longer) prior to the first dose of study drugs
    • Radiotherapy within 14 days of first dose of study drugs. Palliative radiotherapy particularly limited field and stereotactic body radiation therapy to non-target lesions should be allowed.
    • Inhibitors or inducers of the enzymes and transporters being tested in this study within 14 days of starting study drugs
    • Sensitive substrates of or CYP2C8 with a narrow therapeutic index within 14 days of starting study drugs
    • Herbal preparations/medications known to be strong or moderate CYP3A4 inhibitors or inducers or to have other significant potential for interaction with rezatapopt within 14 days of starting study drugs
    • Foods or drinks with CYP3A inhibition potential (e.g., grapefruit, grapefruit juice, Seville orange juice, pomelos, starfruits) within 14 days of starting study drugs
  3. Known or suspected significant , intolerance, or allergy to rezatapopt, metformin, rosuvastatin, repaglinide, or midazolam or any of their or medicinal products with similar chemical structures, food, or other substances
  4. Previously untreated , , or spinal cord compression due to disease. Patients who have received radiation or surgery for brain metastases are eligible if therapy was completed at least 4 weeks prior to starting study drugs, there is no evidence of central nervous system disease progression or mild neurologic symptoms, and there is no requirement for chronic therapy.
  5. Stroke or within 6 months before screening
  6. , uncontrolled heart diseases currently or within the last 6 months including:

    • >470 msec obtained as the mean from 3 consecutive resting ECGs. A QTcF value corrected for wide QRS >120 msec (QTcFBBB) should be used in place of QTcF for patients with non-clinically significant wide QRS >120 msec due to a pacemaker or bundle branch block.
    • Uncontrolled hypertension
  7. Active gastrointestinal disease that may interfere significantly with the absorption, distribution, metabolism, or excretion of study drug
  8. History of prior organ transplant
  9. Presence of other active invasive cancers other than the one treated in this study within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix, or other local tumors considered cured by local treatment
  10. Known, active, uncontrolled virus infection (i.e., viral load above the limit of quantification), virus infection (i.e., viral load above the limit of quantification), or infection (viral load >400 copies/mL of blood). Patients whose viral load is controlled should be on established antiretroviral therapy for at least 4 weeks before receiving their first dose of study drugs.
  11. Patients with a known KRAS single-nucleotide variation (SNV) mutation
  12. Major surgery (excluding placement of vascular access) within 4 weeks of first dose of study drugs

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    Part A, Days 1-24 and Part B, Cycles 1-33

    Patients will receive a cocktail of metformin and rosuvastatin after a morning meal on Day 1. Serial PK samples will be collected on Days 1-3. Days 2-5 will serv as a washout period. On Day 2, patients will receive a cocktail of repaglinide and midazolam. Serial PK samples will be collected on Days 2-3. Days 3-5 will serve as a washout period. On Days 6-21 patients will receive rezatapopt with serial PK samples taken on Days 6-7 and sparse PK on Day 14. On Day 22, patients will receive rezatapopt concurrently with a cocktail of metformin and rosuvastatin. Serial PK samples will be collected on Days 22-24. On Day 23, patients will receive rezatapopt concurrently with a cocktail of repaglinide and midazolam. Serial PK samples will be collected on Days 23-24. In Part B, patients will receive rezatapopt as 2000 mg PO QD in 21-day cycles through Cycle 33 (approximately 2 years) or until another discontinuation criterion is met.

    Drug: metformin hydrochloride 500 mg tablet · Drug: rosuvastatin 10 mg tablet · Drug: repaglinide 0.5 mg tablet · Drug: midazolam hydrochloride syrup · Drug: rezatapopt

Interventions

06

What researchers measure

Primary outcomes

  1. Metformin Cmax geometric mean ratio

    Geometric mean metformin peak concentration (Cmax) when administered with rezatapopt versus metformin alone.

    Time frame: Day 1 to Day 24 of Part A

  2. Rosuvastatin Cmax geometric mean ratio

    Geometric mean rosuvastatin peak concentration (Cmax) when administered with rezatapopt versus rosuvastatin alone.

    Time frame: Day 1 to Day 24 of Part A

  3. Repaglinide Cmax geometric mean ratio

    Geometric mean repaglinide peak concentration (Cmax) when administered with rezatapopt versus repaglinide alone

    Time frame: Day 1 to Day 24 of Part A

  4. Midazolam Cmax geometric mean ratio

    Geometric mean midazolam peak concentration (Cmax) when administered with rezatapopt versus midazolam alone

    Time frame: Day 1 to Day 24 of Part A

  5. Metformin AUC0-t geometric mean ratio

    Geometric mean metformin area under the concentration-time curve from pre-dose (time 0) to t post-dose (AUC0-t) when administered with rezatapopt versus metformin alone

    Time frame: Day 1 to Day 24 of Part A

  6. Rosuvastatin AUC0-t geometric mean ratio

    Geometric mean rosuvastatin area under the concentration-time curve from pre-dose (time 0) to t post-dose (AUC0-t) when administered with rezatapopt versus rosuvastatin alone

    Time frame: Day 1 to Day 24 of Part A

  7. Repaglinide AUC0-t geometric mean ratio

    Geometric mean repaglinide area under the concentration-time curve from pre-dose (time 0) to t post-dose (AUC0-t) when administered with rezatapopt versus repaglinide alone

    Time frame: Day 1 to Day 24 of Part A

  8. Midazolam AUC0-t geometric mean ratio

    Geometric mean midazolam area under the concentration-time curve from pre-dose (time 0) to t post-dose (AUC0-t) when administered with rezatapopt versus midazolam alone

    Time frame: Day 1 to Day 24 of Part A

  9. PK profile of metformin - area under the concentration-time curve from pre-dose (time 0) to 24 h post-dose (AUC0-24)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of metformin

    Time frame: Day 1 to Day 24 of Part A

  10. PK profile of rosuvastatin - area under the concentration-time curve from pre-dose (time 0) to 24 h post-dose (AUC0-24)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rosuvastatin

    Time frame: Day 1 to Day 24 of Part A

  11. PK profile of repaglinide - area under the concentration-time curve from pre-dose (time 0) to 24 h post-dose (AUC0-24)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of repaglinide

    Time frame: Day 1 to Day 24 of Part A

  12. PK profile of midazolam - area under the concentration-time curve from pre-dose (time 0) to the time 24 h post-dose (AUC0-24)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of midazolam

    Time frame: Day 1 to Day 24 of Part A

  13. PK profile of metformin - area under the concentration-time curve from pre-dose (time 0) to 48 h post-dose (AUC0-48)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of metformin

    Time frame: Day 1 to Day 24 of Part A

  14. PK profile of rosuvastatin - area under the concentration-time curve from pre-dose (time 0) to 48 h post-dose (AUC0-48)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rosuvastatin

    Time frame: Day 1 to Day 24 of Part A

  15. PK Profile of Metformin - Time of Peak Concentration (Tmax)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of metformin

    Time frame: Day 1 to Day 24 of Part A

  16. PK Profile of Rosuvastatin - Time of Peak Concentration (Tmax)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rosuvastatin

    Time frame: Day 1 to Day 24 of Part A

  17. PK Profile of Repaglinide - Time of Peak Concentration (Tmax)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of repaglinide

    Time frame: Day 1 to Day 24 of Part A

  18. PK Profile of Midazolam - Time of Peak Concentration (Tmax)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of midazolam

    Time frame: Day 1 to Day 24 of Part A

Secondary outcomes

  1. Determine the incidence and severity of adverse events to characterize the safety of rezatapopt alone or co-administered with metformin and rosuvastatin, or repaglinide and midazolam

    Number of participants with adverse events, with severity assessed using CTCAE v5.0

    Time frame: From Day 6 to 24 of Part A

  2. Assess the safety and tolerability of multiple doses of rezatapopt alone or co-administered with metformin and rosuvastatin, or repaglinide and midazolam

    Changes from baseline of physical examinations.

    Time frame: Day 6 to 24 of Part A.

  3. Assess the safety and tolerability of multiple doses of rezatapopt alone or co-administered with metformin and rosuvastatin, or repaglinide and midazolam

    Changes from baseline of vital signs

    Time frame: Day 6 to Day 24 of Part A

  4. Assess the safety and tolerability of multiple doses of rezatapopt alone or co-administered with metformin and rosuvastatin, or repaglinide and midazolam

    Changes from baseline of clinical laboratory values

    Time frame: Day 6 to Day 24 of Part A

  5. Assess the safety and tolerability of multiple doses of rezatapopt alone or co-administered with metformin and rosuvastatin, or repaglinide and midazolam

    Changes from baseline of 12 lead triplicate ECGs (electrocardiogram)

    Time frame: Day 6 to Day 24 of Part A

  6. Assess the safety and tolerability of multiple doses of rezatapopt alone or co-administered with metformin and rosuvastatin, or repaglinide and midazolam

    Changes in baseline of Eastern Cooperative Oncology Group Performance Status (ECoG) using a scale of 0-5

    Time frame: Day 6 to Day 24 of Part A

  7. PK profile of rezatapopt and its metabolites, M13 and M14 - peak concentration (Cmax)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt and its metabolites, M13 and M14.

    Time frame: Day 6 to Day 24 of Part A

  8. PK profile of rezatapopt and its metabolites, M13 and M14 - area under the concentration-time curve from pre-dose (time 0) to the time t post-dose (AUC0-t)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt and its metabolites, M13 and M14.

    Time frame: Day 6 to Day 24 of Part A

  9. PK profile of rezatapopt and its metabolites, M13 and M14 - time of peak concentration (Tmax)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt and its metabolites, M13 and M14.

    Time frame: Day 6 to Day 24 of Part A

  10. PK profile of rezatapopt and its metabolites, M13 and M14 - area under the concentration-time curve from pre-dose (time 0) to the time 24 h post-dose (AUC0-24)

    Pharmacokinetic parameters will be determined by non-compartmental methods using pharmacokinetic profile of rezatapopt and its metabolites, M13 and M14.

    Time frame: Day 6 to Day 24 of Part A

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2026
First posted
Jan 28, 2026
StartActual
Feb 4, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Jan 2028
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07372625
Lead sponsor
PMV Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Jan 28, 2026
Start date
Feb 4, 2026
Primary completion
Mar 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Aug 12, 2026

Study contacts

SCRI Medical Support Center
Contact
SCRI.InnovationsMedical@scri.com
1-615-329-7286
PMV Pharma Clinical Study Information Center
Contact
clinicaltrials@pmvpharma.com
609-235-4038
Deepak Bhamidipati, MD
study chair · SCRI

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Repaglinide · Rezatapopt

Start the discussion